Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Zepbound

Skip the Waiting Room: Your 2025 Guide to Getting Zepbound Online Safely

The year 2025 marks a new era in digital healthcare in Canada, where patients no longer need to wait weeks for appointments or stand in long lines at pharmacies to receive vital medications.

New Walmart Partnership to Let Patients Buy Eli Lilly's Zepbound Without Insurance Hassles

New Walmart Partnership to Let Patients Buy Eli Lilly's Zepbound Without Insurance Hassles

Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.

International Business Times

Daily weight loss pill achieves main goal in late-stage trial

Daily weight loss pill achieves main goal in late-stage trial

Data from an earlier study of the drug in patients without diabetes sent company shares tumbling

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

2 Outstanding ‘Strong Buy’ Stocks to Grab in August

These two stocks offer a rare combination of income and growth.

Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert

Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access despite strong market demand.

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

inkl

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity

Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity

Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down.

The Future of Weight-Loss Drugs for Investors

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

People

Ania Jastreboff

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Eli Lilly and Company

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

316,354 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play